Summit Therapeutics Inc. Basic Shares Outstanding (Weighted Average)
Summit Therapeutics Inc. (SMMT) reported Basic Shares Outstanding (Weighted Average) of 778.18 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfSharesOutstandingBasic · last filed 2026-07-23
- Summit Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-06-30 was 778.18M shares, a 4.79% increase year-over-year.
- Summit Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2026-03-31 was 775.46M shares, a 5.06% increase year-over-year.
- Summit Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-12-31 was 766.64M shares, a 3.93% increase year-over-year.
- Summit Therapeutics Inc. weighted average number of shares outstanding, basic for the quarter ending 2025-09-30 was 743.42M shares, a 2.31% increase year-over-year.
- Summit Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2025 was 747.70M shares, a 4.06% increase from fiscal 2024.
- Summit Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2024 was 718.54M shares, a 15.96% increase from fiscal 2023.
- Summit Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2023 was 619.65M shares, a 220.50% increase from fiscal 2022.
- Summit Therapeutics Inc. weighted average number of shares outstanding, basic for fiscal 2022 was 193.34M shares, a 46.78% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Basic 3 month | Weighted Average Number of Shares Outstanding, Basic 3 month as first filed | Weighted Average Number of Shares Outstanding, Basic 6 month | Weighted Average Number of Shares Outstanding, Basic 6 month as first filed | Weighted Average Number of Shares Outstanding, Basic 9 month | Weighted Average Number of Shares Outstanding, Basic 9 month as first filed | Weighted Average Number of Shares Outstanding, Basic 11 month | Weighted Average Number of Shares Outstanding, Basic 11 month as first filed | Weighted Average Number of Shares Outstanding, Basic 12 month | Weighted Average Number of Shares Outstanding, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | 778.18M shares 10-Q · filed 2026-07-23 | 776.82M shares 10-Q · filed 2026-07-23 | 773.43M shares derived: average of 3 quarters · filed 2026-07-23 | 765.93M shares derived: average of 4 quarters · filed 2026-07-23 | ||||||
| 2026-03-31 | 775.46M shares 10-Q · filed 2026-04-30 | 771.05M shares derived: average of 2 quarters · filed 2026-04-30 | 761.84M shares derived: average of 3 quarters · filed 2026-04-30 | 757.03M shares derived: average of 4 quarters · filed 2026-07-23 | ||||||
| 2025-12-31 | 766.64M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 755.03M shares derived: average of 2 quarters · filed 2026-02-23 | 750.89M shares derived: average of 3 quarters · filed 2026-07-23 | 747.70M shares 10-K · filed 2026-02-23 | ||||||
| 2025-09-30 | 743.42M shares 10-Q · filed 2025-10-20 | 743.02M shares derived: average of 2 quarters · filed 2026-07-23 | 741.39M shares 10-Q · filed 2025-10-20 | 740.44M shares derived: average of 4 quarters · filed 2026-07-23 | ||||||
| 2025-06-30 | 742.62M shares 10-Q · filed 2026-07-23 | 740.36M shares 10-Q · filed 2026-07-23 | 739.45M shares derived: average of 3 quarters · filed 2026-07-23 | 736.25M shares derived: average of 4 quarters · filed 2026-07-23 | ||||||
| 2025-03-31 | 738.08M shares 10-Q · filed 2026-04-30 | 737.87M shares derived: average of 2 quarters · filed 2026-04-30 | 734.13M shares derived: average of 3 quarters · filed 2026-04-30 | 727.57M shares derived: average of 4 quarters · filed 2026-04-30 | ||||||
| 2024-12-31 | 737.66M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 732.16M shares derived: average of 2 quarters · filed 2026-02-23 | 724.07M shares derived: average of 3 quarters · filed 2026-02-23 | 718.54M shares 10-K · filed 2026-02-23 | ||||||
| 2024-09-30 | 726.66M shares 10-Q · filed 2025-10-20 | 717.28M shares derived: average of 2 quarters · filed 2025-10-20 | 712.17M shares 10-Q · filed 2025-10-20 | 709.46M shares derived: average of 4 quarters · filed 2026-02-23 | ||||||
| 2024-06-30 | 707.90M shares 10-Q · filed 2025-08-11 | 704.84M shares 10-Q · filed 2025-08-11 | 703.72M shares derived: average of 3 quarters · filed 2026-02-23 | 702.23M shares derived: average of 4 quarters · filed 2026-02-23 | ||||||
| 2024-03-31 | 701.79M shares 10-Q · filed 2025-05-01 | 701.63M shares derived: average of 2 quarters · filed 2026-02-23 | 700.34M shares derived: average of 3 quarters · filed 2026-02-23 | 699.67M shares derived: average of 4 quarters · filed 2026-02-23 | ||||||
| 2023-12-31 | 701.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | 699.61M shares derived: average of 2 quarters · filed 2026-02-23 | 698.97M shares derived: average of 3 quarters · filed 2026-02-23 | 619.65M shares 10-K · filed 2026-02-23 | ||||||
| 2023-09-30 | 697.74M shares 10-Q · filed 2024-10-30 | 697.71M shares derived: average of 2 quarters · filed 2024-10-30 | 592.37M shares 10-Q · filed 2024-10-30 | 515.35M shares derived: average of 4 quarters · filed 2025-02-24 | ||||||
| 2023-06-30 | 697.69M shares 10-Q · filed 2024-08-06 | 538.81M shares 10-Q · filed 2024-08-06 | 454.55M shares derived: average of 3 quarters · filed 2025-02-24 | 393.14M shares derived: average of 4 quarters · filed 2025-02-24 | ||||||
| 2023-03-31 | 378.16M shares 10-Q · filed 2024-05-01 | 332.98M shares derived: average of 2 quarters · filed 2025-02-24 | 291.63M shares derived: average of 3 quarters · filed 2025-02-24 | 253.75M shares derived: average of 4 quarters · filed 2025-02-24 | ||||||
| 2022-12-31 | 287.81M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | 248.36M shares derived: average of 2 quarters · filed 2025-02-24 | 212.28M shares derived: average of 3 quarters · filed 2025-02-24 | 193.34M shares 10-K · filed 2025-02-24 | ||||||
| 2022-09-30 | 208.91M shares 10-Q · filed 2023-11-07 | 148.58M shares 10-Q · filed 2022-11-09 | 174.51M shares derived: average of 2 quarters · filed 2023-11-07 | 161.85M shares 10-Q · filed 2023-11-07 | 115.11M shares 10-Q · filed 2022-11-09 | 185.15M shares derived: average of 4 quarters · filed 2023-11-07 | ||||
| 2022-06-30 | 140.11M shares 10-Q · filed 2023-08-09 | 99.65M shares 10-Q · filed 2022-08-11 | 140.08M shares 10-Q · filed 2023-08-09 | 99.63M shares 10-Q · filed 2022-08-11 | 177.23M shares derived: average of 3 quarters · filed 2023-08-09 | 157.67M shares derived: average of 4 quarters · filed 2023-08-09 | ||||
| 2022-03-31 | 140.04M shares 10-Q · filed 2023-05-11 | 98.07M shares 10-Q · filed 2022-05-11 | 195.79M shares derived: average of 2 quarters · filed 2023-05-11 | 163.52M shares derived: average of 3 quarters · filed 2023-05-11 | 145.66M shares derived: average of 4 quarters · filed 2023-05-11 | |||||
| 2021-12-31 | 251.54M shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | 175.26M shares derived: average of 2 quarters · filed 2023-03-09 | 147.53M shares derived: average of 3 quarters · filed 2023-03-09 | 131.71M shares 10-K · filed 2023-03-09 | 92.24M shares 10-K · filed 2022-03-17 | |||||
| 2021-09-30 | 98.97M shares 10-Q · filed 2022-11-09 | 97.45M shares 10-Q · filed 2021-11-15 | 95.52M shares derived: average of 2 quarters · filed 2022-11-09 | 91.77M shares 10-Q · filed 2022-11-09 | 90.36M shares 10-Q · filed 2021-11-15 | 87.57M shares derived: average of 4 quarters · filed 2022-12-21 | ||||
| 2021-06-30 | 92.07M shares 10-Q · filed 2022-08-11 | 90.65M shares 10-Q · filed 2021-08-12 | 88.11M shares 10-Q · filed 2022-08-11 | 86.76M shares 10-Q · filed 2021-08-12 | 83.77M shares derived: average of 3 quarters · filed 2022-12-21 | 79.63M shares derived: average of 4 quarters · filed 2022-12-21 | ||||
| 2021-03-31 | 82.82M shares 10-Q · filed 2022-05-11 | 79.62M shares derived: average of 2 quarters · filed 2022-12-21 | 75.49M shares derived: average of 3 quarters · filed 2022-12-21 | 73.42M shares derived: average of 4 quarters · filed 2022-12-21 | ||||||
| 2020-12-31 | 76.42M shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2022-12-21 | 71.82M shares derived: average of 2 quarters · filed 2022-12-21 | 70.29M shares derived: average of 3 quarters · filed 2022-12-21 | 69.52M shares 10-K/A · filed 2022-12-21 | ||||||
| 2020-09-30 | 67.23M shares 10-Q · filed 2021-11-15 | 67.23M shares 10-Q · filed 2020-11-16 | 67.23M shares derived: average of 2 quarters · filed 2021-11-15 | 67.23M shares 10-Q · filed 2021-11-15 | 67.23M shares 10-Q · filed 2020-11-16 | |||||
| 2020-06-30 | 67.23M shares 10-Q · filed 2021-08-12 | 67.23M shares 8-K · filed 2020-09-29 | 67.22M shares 10-Q · filed 2021-08-12 | 67.22M shares 8-K · filed 2020-09-29 | ||||||
| 2020-03-31 | 67.22M shares 10-Q · filed 2021-05-17 | |||||||||
| 2019-12-31 | 32.83M shares 10-K · filed 2021-03-31 | 32.83M shares 8-K · filed 2020-09-29 | ||||||||
| 2019-09-30 | 32.10M shares 10-Q · filed 2020-11-16 | 32.10M shares derived: average of 2 quarters · filed 2020-11-16 | 31.63M shares 10-Q · filed 2020-11-16 | |||||||
| 2019-06-30 | 32.09M shares 8-K · filed 2020-09-29 | 31.39M shares 8-K · filed 2020-09-29 | ||||||||
| 2019-01-31 | 17.14M shares 10-K · filed 2021-03-31 | 17.14M shares 8-K · filed 2020-09-29 | ||||||||
| 2018-01-31 | 13.09M shares 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |